Jury Favors AbbVie in the Fifth TRT Bellwether Trial

Jury Favors AbbVie in the Fifth TRT Bellwether Trial

Introduction

AbbVie Inc. won yet another lawsuit on June 14 over claims that its AndroGel caused a man's deep vein thrombosis (DVT). This is the fifth testosterone replacement therapy bellwether trial, which began on June 5, in the Illinois State Court for a plaintiff.

The plaintiff filed a lawsuit in 2014 after suffering from DVT in April 2013 and in late 2015. He blamed Androgel use for both incidents. The federal jury dismissed the plaintiff's allegation that AndroGel's use led to his blood clot. Last month, a plaintiff and his wife lost to AbbVie, as the jury stated that the drug was not responsible for his bilateral pulmonary embolism that occurred in February 2008.

Testosterone Replacement Therapy lawsuits are centralized before U.S. District Judge Matthew Kennelly in the Northern District of Illinois as a part of federal multidistrict litigation (MDL No. 2545; In Re: Testosterone Replacement Therapy Products Liability Litigation).